COMy 2024 | An update on the MajesTEC-1 trial: the efficacy of less frequent dosing of teclistamab in RRMM
Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, gives an update on the MajesTEC-1 trial (NCT04557098), investigating teclistamab in relapsed/refractory multiple myeloma (RRMM). Patients switched to a less frequent dosing schedule have maintained their responses with a lower incidence of grade 3 or higher infections. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda.
Consulting: Abbvie, Amgen, BMS, Celgene, EdoPharma, Genentech, Gilead, GSK, Janssen, Oncopeptides, Sanofi, Seattle Genetics, SecuraBio, SkylineDX, Takeda, TeneoBio.
Speaker: Amgen, BMS, Janssen, Sanofi.
